All In Biotech

Drug Trial Radar · NCT05979779

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

219

Actual

Start

Sep 5, 2023

Primary completion

Jan 21, 2025

Study completion Jun 2025

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
  • Fatty Liver

Interventions

  • HU6Drug

    HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)Time frame: 6 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • ProSciento CRU

    Chula Vista, California

  • Velocity Clinical Research

    Los Angeles, California

  • Catalina Research Institute

    Montclair, California

  • Northern California Research Center

    Sacramento, California

  • Metro Clinical Trials

    San Bernardino, California

  • Synergy Healthcare

    Bradenton, Florida

  • ABMED Clinical Research Corp.

    Cape Coral, Florida

  • Southwest General Healthcare Center

    Fort Myers, Florida

  • Miami Clinical Research

    Miami, Florida

  • Advanced Clinical Research

    Miami, Florida

  • Century Research, LLC

    Miami, Florida

  • Entrust Clinical Research

    Miami, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • Tandem Clinical Research

    Marrero, Louisiana

  • CenExel HRI

    Berlin, New Jersey

  • Lillestol Research

    Fargo, North Dakota

  • IMA Clinical Research-Austin

    Austin, Texas

  • Mt Olympus Medical Research

    Houston, Texas

  • Houston Research Institute

    Houston, Texas

  • Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.